

THE University of Vermont CANCER CENTER

The eALERT is an internal newsletter sent semi-monthly.
Please send submissions for the eALERT to [Sarah Keblin](#) by 4 PM Wednesday for
submission in the current issue.

June 29, 2017

Molecular Therapeutics of Cancer Research Conference: July 16-19

UVM Cancer Center Clinical Trial Office Highlight

Summer Night's Dream a Success for UVM Cancer Center and Hope Lodge

Publications and Announcements

Funding Opportunities--MANY NEW!

Ongoing Events

Event Spotlight

July 21

[Komen New England
25th Anniversary
Race for the Cure](#)

Molecular Therapeutics of Cancer Research Conference in Burlington

A Molecular Therapeutics of Cancer Research Conference will be hosted in Burlington, VT from **July 16-19**. Sponsored by Norris Cotton Cancer Center, UVM Cancer Center and the Cancer Molecular Therapeutics Research Association, the meeting objective is to provide a forum for presentation and discussion of contemporary research in the field of cancer drug development and therapy.

Manchester, VT

Funds raised benefit this year's 20th Annual Women's Health and Cancer Conference!

Events Calendar

July 2017

UV Safety Month

16-19 Molecular Therapeutics of Cancer Research Conference; sponsored by UVM Cancer Center, Norris Cotton Cancer Center and the Cancer Molecular Therapeutics Research Association; **Burlington, VT.** [Register here.](#)

21 25th Anniversary [Komen Race for the Cure](#), Manchester, NH.

October 2017

*Breast cancer awareness month
Liver cancer awareness month*

6 SAVE THE DATE: 20th Annual Women's Health and Cancer Conference

November 2017

*Lung cancer awareness month
Pancreatic cancer awareness month*

Modeled after small Gordon-type conferences, the meeting provides an opportunity for young and established researchers to discuss and challenge current paradigms for cancer drug development and therapy, as well as a venue where novel ideas can be presented with anticipation of lively debate.

For a full agenda or to register, [click here.](#)

UVM Cancer Center Clinical Trial Office Highlight

The American Society of Clinical Oncology (ASCO) recently reported "late breaking" news on two trials offered to patients at the UVM Cancer Center as part of national studies.

"Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer," is the headline for the phase III Olympiad trial. Results showed that Olaparib tablet monotherapy yielded improved, progression-free survival compared with standard-of-care chemotherapy among women with HER2-negative metastatic breast cancer and a germline BRCA mutation.


The second ASCO highlight, **"Risk-Based Approach to Chemotherapy Duration Recommended for Stage III Colon Cancer,"** looked at reducing toxicity for patients, and showed evidence that a 3-month chemotherapy course was almost as effective as a 6-month course, and was even more appropriate for low-risk patients.

Community Fundraiser Success

Thanks to the hard work of a dedicated group of community volunteers, the Summer Night's Dream evening fundraiser raised more than \$200,000 for cancer research at the UVM Cancer Center and in support of services at the Lois McClure/Bee Tabakin Hope Lodge.

Many thanks to all who attended, donated and volunteered!

3 SAVE THE DATE: 3rd Annual Men's Health and Cancer Conference



Publications and Announcements

Please send announcements and publication notices to [Sarah Keblin](#) for inclusion in the eALERT and other promotional material

Publications:

[Revisiting Prostate Cancer Screening Practices Among Vermont Primary Care Physicians.](#) Donnelly L, Sternberg KM, Ashikaga T, Plante MK, Perrapato SD.J Community Health. 2017 Jun 15. doi: 10.1007/s10900-017-0384-x. [Epub ahead of print] PMID: 28620736.

[A review of the effects of very low nicotine content cigarettes on behavioral and cognitive performance.](#) Keith DR, Kurti AN, Davis DR, Zvorsky IA, Higgins ST. Prev Med. 2017 Jun 21. pii: S0091-7435(17)30221-9. doi: 10.1016/j.ypmed.2017.06.016. [Epub ahead of print] PMID: 28647546.

[In focus in HCB.](#) Taatjes DJ, Roth J. Histochem Cell Biol. 2017 Jun 22. doi: 10.1007/s00418-017-1592-2. [Epub ahead of print] No abstract available. PMID: 28643083.

[Erratum to: Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome.](#) McKnight TFP, Noffsinger AE, Landry KK, Ahmed O, Wilcox R. Virchows Arch. 2017 Jun 15. doi: 10.1007/s00428-017-2170-7. [Epub ahead of print] No abstract available. PMID: 28616732.

[An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.](#)

Zaidi SK, Perez AW, White ES, **Lian JB**, **Stein JL**, **Stein GS**. Oncotarget. 2017 Jun 20;8(25):39994-40005. doi: 10.18632/oncotarget.18127.PMID: 28611288.

[Significance of positive and inhibitory regulators in the TGF- \$\beta\$ signaling pathway in colorectal cancers.](#)

Coates RF, Gardiner JA, Gao Y, Cortright VM, Mitchell JM, **Ashikaga T**, Skelly J, Yang M.Hum Pathol. 2017 Jun 7. pii: S0046-8177(17)30194-6. doi: 10.1016/j.humpath.2017.05.021. [Epub ahead of print] PMID: 28601657.

[Functional Impairment and Risk of Venous Thrombosis in Older Adults.](#)

Engbers MJ, Blom JW, **Cushman M**, Rosendaal FR, van Hylckama Vlieg A.J Am Geriatr Soc. 2017 Jun 9. doi: 10.1111/jgs.14964. [Epub ahead of print] PMID: 28598535.

[Remote Mutations Induce Functional Changes in Active Site Residues of Human DNA Polymerase \$\beta\$.](#)

Eckenroth BE, Towle-Weicksel JB, Nemec AA, Murphy DL, **Sweasy JB**, **Doublié S**.Biochemistry. 2017 May 9;56(18):2363-2371. doi: 10.1021/acs.biochem.6b01287. Epub 2017 Apr 21.PMID: 28402631.

[Lung-cancer mortality among Vermont granite workers: factors influencing exposure-response evaluation.](#)

Vacek PM, Callas PW.Occup Environ Med. 2017 Mar;74(3):211-217. doi: 10.1136/oemed-2015-103527. Epub 2016 Nov 7.PMID: 27821675.

Funding Opportunities

To find a more complete listing of available funding opportunities, please visit the

[UVM Cancer Center Extramural Funding Opportunities](#) website/

FINAL CALLS:

[Damon Runyon Cancer Research Foundation](#) invites applications for the [Damon Runyon-Rachleff Innovation Award](#), a two-year/\$150,000 per year, with up to two additional years of funding (up to four years total for \$600,000). The Innovation Award supports early career researchers and the proposed research must be novel, exceptionally creative and, if

successful, have the strong potential for high impact in the cancer field. **Application deadline is July 6, 2017.**

Department of Defense (DOD)-U.S. Army Medical Research and Materiel Command (USAMRMC)-Office of Congressionally Directed Medical Research Programs ([CDMRP](#)): Prostate Cancer Research ([PCRP](#)) -[Impact Award](#): up to \$750,000 for a single PI or up to \$2,000,000 for partnered PIs for research in prostate cancer originating from a spectrum of disciplines including basic science, engineering, bioinformatics, population science, psycho-oncology, translational research, and clinical research, including small scale Phase I or II clinical trials. **Letter of intent (required) is due July 7, 2017.**

Department of Defense (DOD)-U.S. Army Medical Research and Materiel Command (USAMRMC)-Office of Congressionally Directed Medical Research Programs ([CDMRP](#)): Prostate Cancer Research ([PCRP](#)) -[Health Disparity Research Award](#) up to \$450,000 to support innovative concepts or methodologies for health disparity research. **Letter of intent (required) is due July 7, 2017.**

FEATURED FUNDING OPPORTUNITIES:

[National Cancer Institute \(NCI\)/NIH/DHHS \[PAR-16-278 Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control \\(R21\\)\]\(#\)](#): supports innovative interventions that improve cancer-related health behavior including diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. **Next deadline is September 7, 2017** with subsequent deadlines until January 7, 2019.

[National Cancer Institute \(NCI\)/NIH/DHHS - \[PAR-16-284 Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award \\(K07\\)\]\(#\)](#): supports career development of junior investigators with research or health professional doctoral degrees who want to become cancer-focused academic researchers in cancer prevention, cancer control, or the behavioral or population sciences. **Next deadline is September 7, 2017; subsequent deadlines of October 12, 2017 and January 7, 2018.**

CONquer canCER Now Award: funds young and innovative cancer researchers focused on cancer genetics, biology and immunology. Approx. 20 researchers receive a \$60,000 Conquer Cancer Now Award per year for the two-year grant cycle. Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology. Concern will not fund clinical trials, cancer epidemiology, or behavioral studies. Now accepting LOI's through **September 7th, 2017**.

Burroughs Welcome Fund Physician Scientist Institutional Award: a five month planning grant of up to \$30,000 to support programs or initiatives aimed at encouraging physicians' participation in research; **proposals due September 28, 2017**.

Cancer Research Institute (CRI)CRI Irvington Postdoctoral Fellowship Program: offers \$175K over three years to fund and train young immunologists and cancer immunologists. Seeks hypothesis-driven, mechanistic studies in both immunology and tumor immunology. **Deadlines are October 1, 2017 and April 1, 2018**.

Ongoing Events

Cancer Biology and Technology Seminar Series (an integrated part of the Biochemistry Seminar Series)
Second Friday of each month at Noon, Given C443.

UVM Cancer Center Grand Rounds

1st, 2nd, 3rd, 5th
Tuesday 8-9am, MedEd 300

UVM Cancer Center Leadership:
Gary S. Stein, PhD, Director
Kate Webster, CRA, Research Center Administrator
Sarah Keblin, Communications Manager